The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI ...

More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus (RSV) for infants, will be available in January, the White House says.

Beyfortus, jointly developed by Sanofi and AstraZeneca, was approved in the European Union in October 2022, in Great Britain in November 2022, and recently received approval in Canada in April 2023.

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. Paris, June 9, 2025. Sanofi is shipping Beyfortus starting in early Q3 to ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.

Sanofi, in collaboration with its partner AstraZeneca, has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.